Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.
| Image |  |
|---|---|
| Description | scientific article published on 25 August 2017 |
| Author/s |
author: Robert P Giugliano Gaetano M. De Ferrari Jose Lopez-Miranda Brian R Ott |
| Publication date | August 28, 2017 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |